NASDAQ:BNTC Benitec Biopharma (BNTC) Stock Price, News & Analysis $9.29 +0.45 (+5.09%) (As of 07/5/2024 08:52 PM ET) Add Compare Share Share Today's Range$8.57▼$9.2950-Day Range$6.30▼$10.4752-Week Range$1.86▼$10.70Volume16,700 shsAverage Volume57,406 shsMarket Capitalization$87.05 millionP/E RatioN/ADividend YieldN/APrice Target$23.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Benitec Biopharma alerts: Email Address Benitec Biopharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside147.6% Upside$23.00 Price TargetShort InterestHealthy0.43% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($7.67) to ($2.88) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.05 out of 5 starsMedical Sector359th out of 879 stocksPharmaceutical Preparations Industry162nd out of 417 stocks 3.5 Analyst's Opinion Consensus RatingBenitec Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageBenitec Biopharma has only been the subject of 2 research reports in the past 90 days.Read more about Benitec Biopharma's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.43% of the float of Benitec Biopharma has been sold short.Short Interest Ratio / Days to CoverBenitec Biopharma has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Benitec Biopharma has recently decreased by 25.78%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldBenitec Biopharma does not currently pay a dividend.Dividend GrowthBenitec Biopharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BNTC. Previous Next 0.6 News and Social Media Coverage Search Interest8 people have searched for BNTC on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Benitec Biopharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Benitec Biopharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.30% of the stock of Benitec Biopharma is held by insiders.Percentage Held by Institutions52.19% of the stock of Benitec Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Benitec Biopharma's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Benitec Biopharma are expected to grow in the coming year, from ($7.67) to ($2.88) per share.Price to Book Value per Share RatioBenitec Biopharma has a P/B Ratio of 77.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Benitec Biopharma's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyObama wins Presidential debate When I said Obama would seek a third term… They called me a conspiracy theorist, they said it couldn’t happen, that the 22nd Amendment makes it impossible. But as I explained on live radio years ago, “he could have a proxy… while he remains in control of the administration much like Putin did in Russia.” Please, watch this now before it’s too late. About Benitec Biopharma Stock (NASDAQ:BNTC)Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.Read More BNTC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BNTC Stock News HeadlinesMay 20, 2024 | markets.businessinsider.comBuy Rating for Benitec Biopharma on Promising Early-Stage Clinical Data and Solid FinancialsMay 13, 2024 | finance.yahoo.comBenitec Biopharma Releases Third Quarter 2024 Financial Results and Provides Operational UpdateJuly 8, 2024 | Porter & Company (Ad)Obama wins Presidential debate When I said Obama would seek a third term… They called me a conspiracy theorist, they said it couldn’t happen, that the 22nd Amendment makes it impossible. But as I explained on live radio years ago, “he could have a proxy… while he remains in control of the administration much like Putin did in Russia.” May 13, 2024 | investorplace.comBNTC Stock Earnings: Benitec Biopharma Misses EPS for Q3 2024May 1, 2024 | finance.yahoo.comBenitec Biopharma to Participate in the Citizens JMP Life Science ConferenceApril 18, 2024 | msn.comWhy Is Gene Therapy Developer Benitec Biopharma Stock Trading Higher On Thursday?April 18, 2024 | finanznachrichten.deBenitec Biopharma Inc.: Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a StudyApril 18, 2024 | msn.comBenitec Biopharma jumps 33% on $40M private financingJuly 8, 2024 | Porter & Company (Ad)Obama wins Presidential debate When I said Obama would seek a third term… They called me a conspiracy theorist, they said it couldn’t happen, that the 22nd Amendment makes it impossible. But as I explained on live radio years ago, “he could have a proxy… while he remains in control of the administration much like Putin did in Russia.” April 18, 2024 | markets.businessinsider.comWhy Benitec Biopharma Is Rising In Pre-market?April 18, 2024 | globenewswire.comBenitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a StudyApril 18, 2024 | globenewswire.comBenitec Biopharma Announces Oversubscribed Private Placement Financing of $40.0 MillionApril 9, 2024 | finance.yahoo.comBenitec Biopharma to Host Virtual R&D Day to Discuss BB-301 Clinical Program in Oculopharyngeal Muscular Dystrophy on April 18, 2024March 24, 2024 | insidermonkey.com11 Best ASX Stocks To Buy NowFebruary 25, 2024 | msn.comBenitec Biopharma (BNTC) Price Target Increased by 66.67% to 10.20February 13, 2024 | finance.yahoo.comBenitec Biopharma Releases Second Quarter 2024 Financial Results and Provides Operational UpdateNovember 30, 2023 | finance.yahoo.comHere's Why Benitec Biopharma Inc.'s (NASDAQ:BNTC) CEO Compensation Is The Least Of Shareholders ConcernsNovember 30, 2023 | finance.yahoo.comBenitec Biopharma Announces First Subject Dosed in Phase 1b/2a Clinical Trial for Gene Therapy Candidate BB-301 for the Treatment of Oculopharyngeal Muscular DystrophySee More Headlines Receive BNTC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Benitec Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2024Today7/07/2024Next Earnings (Estimated)9/19/2024Fiscal Year End6/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:BNTC CUSIPN/A CIK1808898 Webwww.benitec.com Phone510-780-0819Fax61 (0)3 9966-9923Employees16Year FoundedN/APrice Target and Rating Average Stock Price Target$23.00 High Stock Price Target$30.00 Low Stock Price Target$16.00 Potential Upside/Downside+147.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,560,000.00 Net MarginsN/A Pretax Margin-309,885.78% Return on Equity-175.36% Return on Assets-127.85% Debt Debt-to-Equity Ratio0.01 Current Ratio4.18 Quick Ratio4.18 Sales & Book Value Annual Sales$80,000.00 Price / Sales1,088.09 Cash FlowN/A Price / Cash FlowN/A Book Value$0.12 per share Price / Book77.42Miscellaneous Outstanding Shares9,370,000Free Float8,965,000Market Cap$87.05 million OptionableNo Data Beta0.91 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesDr. Jerel A. Banks M.D. (Age 49)Ph.D., Executive Chairman & CEO Comp: $848.07kMs. Megan Joan Boston BComm (Age 52)CA, Dip., GAICD, Executive Director Comp: $439.17kDr. Michael GrahamHead of Discovery & Founding ScientistDr. Claudia KlothSenior Vice President of ManufacturingKey CompetitorsKorro BioNASDAQ:KRROSilverback TherapeuticsNASDAQ:SBTXKamadaNASDAQ:KMDAVerrica PharmaceuticalsNASDAQ:VRCANeoleukin TherapeuticsNASDAQ:NLTXView All CompetitorsInstitutional OwnershipGAMMA Investing LLCBought 1,884 shares on 7/2/2024Ownership: 0.058%Janus Henderson Group PLCBought 64,092 shares on 5/16/2024Ownership: 9.440%View All Institutional Transactions BNTC Stock Analysis - Frequently Asked Questions How have BNTC shares performed this year? Benitec Biopharma's stock was trading at $3.23 on January 1st, 2024. Since then, BNTC stock has increased by 187.6% and is now trading at $9.29. View the best growth stocks for 2024 here. How were Benitec Biopharma's earnings last quarter? Benitec Biopharma Inc. (NASDAQ:BNTC) issued its quarterly earnings data on Monday, May, 13th. The biotechnology company reported ($1.64) EPS for the quarter. When did Benitec Biopharma's stock split? Shares of Benitec Biopharma reverse split on the morning of Wednesday, July 26th 2023. The 1-17 reverse split was announced on Wednesday, July 26th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, July 26th 2023. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split. When did Benitec Biopharma IPO? Benitec Biopharma (BNTC) raised $0 in an initial public offering on Thursday, August 6th 2015. The company issued 0 shares at $0.00 per share. BMO Capital Markets and Maxim Group LLC acted as the underwriters for the IPO and Roth Capital Partners was co-manager. Who are Benitec Biopharma's major shareholders? Top institutional investors of Benitec Biopharma include GAMMA Investing LLC (0.06%). View institutional ownership trends. How do I buy shares of Benitec Biopharma? Shares of BNTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Benitec Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Benitec Biopharma investors own include Amarin (AMRN), Pfizer (PFE), Amicus Therapeutics (FOLD), Sorrento Therapeutics (SRNE), Arbutus Biopharma (ABUS), Aldeyra Therapeutics (ALDX) and AVEO Pharmaceuticals (AVEO). This page (NASDAQ:BNTC) was last updated on 7/8/2024 by MarketBeat.com Staff From Our PartnersWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredI’m giving you the name of this investment for freeThis key unlocks a new pathway to wealth that has been kept hidden from you for decades. In my new documen...Porter & Company | SponsoredOperation Replace Biden is a GoLast night’s debate proved me right: Joe Biden will be replaced. I’ve been making this warning for months… ...The Freeport Society | SponsoredBiden to drop out; finish out his term?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Weiss Ratings | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | SponsoredObama’s DNC coupAs we approach the Democratic National Convention in August... many sense a Biden swap-out is looming. In f...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Benitec Biopharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Benitec Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
